Drug Topics July/August 2024

The FDA approved imetelstat (Rytelo) in June 2024.

Our congressional representatives have plenty of interaction with PBM lobbyists. It’s time they hear from patients as well.

The composition of the latest flu vaccine has changed. Here’s what pharmacists need to know.

An interim FTC report outlined how the rise of vertical integration and concentration has led to devastating results for both patients and fragile pieces of the health care delivery system.

Pfizer joins Eli Lilly and Novo Nordisk in the development of oral GLP-1 receptor agonist candidates.

Three posters presented at the American Diabetes Association 84th Scientific Sessions looked into the current landscape of GLP-1s.

Research presented at the American Diabetes Association 84th Scientific Sessions suggests a population approach to CGM use could be beneficial.

The updates follow the Advisory Committee for Immunization Practice meeting held June 26 to 28, 2024.

Two posters presented at the American Diabetes Association 84th Scientific Sessions looked into the impact of glucagon-like peptide-1 receptor agonists in type 1 diabetes management.

Two posters presented at the American Diabetes Association 84th Scientific Sessions looked at challenges of remote CGM in older populations and after discharge from the hospital.

Two abstracts presented at the American Diabetes Association 84th Scientific Sessions explored how positive user experiences with a CGM can lead to better patient outcomes.

The first-in-class selective dual PDE3 and PDE4 inhibitor from Verona Pharma is the first inhaled product with a novel mechanism of action approved to treat COPD in over 20 years.

Cases of Dengue virus—the most common global arboviral disease—are on the rise.

The vaccine covers 8 serotypes not currently covered by any FDA-approved pneumococcal vaccines.

The therapy from AstraZeneca is indicated to improve glycemic control in patients aged 10 years or older.

The Psychopharmacologic Drugs Advisory Committee voted 10-1 that the benefits of MDMA do not outweigh its potential risks.

Unregulated tianeptine, often referred to as “gas station heroin,” has led to serious adverse effects. But while health officials warn the public about its potential dangers, others are concerned stigmatization could ruin any future chance of the drugs medicinal use.